The surge in interest for developing therapeutic antibodies in the last few years has led to increased demand for reliable cell-based assays to assess the ability of these antibodies to elicit ADCC.
In this white paper, we present data on the quantification of ADCC using cell-based iLite ADCC bioassays. In addition, we compare this technology to a traditional method based on NFAT effector cells and wild-type target cells.